Stoke Therapeutics zorevunersen receives Breakthrough Therapy Designation

Stoke Therapeutics (STOK) announced that it has received Breakthrough Therapy Designation from the FDA for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. Zorevunersen is being developed as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.